ľŌ

ľŪ

ļЛ

Sianature

PTO/SB/05 (11-00)

June 15, 2001

Approved for use through 10/31/2002, OMB 0651-0032

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## UTILITY PATENT APPLICATION TRANSMITTAL

Attorney Docket No. BERLX-88

First Inventor Edward M. CROZE et al.

Title NOVEL INTERFERON FOR THE TREATMENT OF MULTIPLE SCLEROSIS

Express Mail Label No. (Only for new nonprovisional applications under 37 C.F.R. 1.53(b)) Assistant Commissioner for Patents APPLICATION ELEMENTS ADDRESS TO: **Box Patent Application** See MPEP chapter 600 concerning utility patent application contents. Washington, DC 20231 Fee Transmittal Form (e.g., PTO/SB/17) CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) (Submit an original and a duplicate for fee processing) 8. Nucleotide and/or Amino Acid Sequence Submission 2. 🔲 Applicant claims small entity status. See 37 CFR 1.27. (if applicable, all necessary) a. Computer Readable Form (CRF) з. 🔯 [Total Pages 45 Specification (preferred arrangement set forth below) b. Specification Sequence Listing on: Descriptive title of the Invention i. CD-ROM or CD-R (2 copies); or Cross References to Related Applications ii. 🔲 paper - Statement Regarding Fed sponsored R & D c. Statements verifying identity of above copies - Reference to sequence listing, a table, **ACCOMPANYING APPLICATIONS PARTS** or a computer program listing appendix - Background of the Invention 9. Assignment Papers (cover sheet & document(s)) - Brief Summary of the Invention - Brief Description of the Drawings ( if filed)
- Detailed Description 37 C.F.R.§3.73(b) Statement 10. ☐ Power of (when there is an assignee) Attorney - Claim(s) - Abstract of the Disclosure 11. English Translation Document (if applicable) Copies of IDS 4. [Total Sheets 15 12. 🗌 Information Disclosure Drawing(s) (35 U.S.C.113) Citations Statement (IDS)/PTO-1449 (Total Pages 5. Oath or Declaration **Preliminary Amendment** a. Newly executed (original or copy) 14. 🛛 Return Receipt Postcard (MPEP 503) b. Copy from a prior application (37 CFR 1.63 (d)) (Should be specifically itemized) (for a continuation/divisional with Box 18 completed) 15. 🔲 Certified Copy of Priority Document(s) i. DELETION OF INVENTOR(S) (if foreign priority is claimed) Signed statement attached deleting inventor(s) 16. Request and Certification under 35 U.S.C. 122 named in the prior application, see 37 CFR (b)(2)(B)(i). Applicant must attach form PTO/SB/35 1.63(d)(2) and 1.33(b). or its equivalent. 6. Application Data Sheet. See 37 CFR 1.76 17. Other: 18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: ☐ Continuation-in-part (CIP) of prior application No: \_ ☐ Continuation □ Divisional Group / Art Unit: Examiner Prior application information: For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts. 17. CORRESPONDENCE ADDRESS or 🗆 Correspondence address below Customer Number or Bar Code Label 23599 Name Address City Zip Code State Fax Telephone Country Name (Print/Type) Anthony J. Zelano Registration No. (Attorney/Agent) 27.969

Burden Hour Statement: This form is estimated to take 8.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Office, U.S. Patient and Trademark Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patients. Box Patient Application (Washington 2023).